Afuco™ Anti-HIV-1 ADCC Therapeutic Antibody (Suvizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to HIV-1. Itolizumab (INN, trade name Alzumab) is a 'first in class' humanized IgG1 monoclonal antibody. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation. A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo. Biocon has received marketing authorization for the drug from the Drugs Controller General of India (DCGI).
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-068 |
| Pricing | Inquiry |
| Host | Human |
| Target | HIV-1 |
| Species Reactivity | HIV-1 |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IP, FC, FuncS, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |